256 related articles for article (PubMed ID: 22128155)
21. Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates.
Li S; Zhou Y; Wang R; Zhang H; Dong Y; Ip C
Mol Cancer Ther; 2007 Mar; 6(3):1031-8. PubMed ID: 17339365
[TBL] [Abstract][Full Text] [Related]
22. Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells.
Niiya M; Niiya K; Shibakura M; Asaumi N; Yoshida C; Shinagawa K; Teshima T; Ishimaru F; Ikeda K; Tanimoto M
Oncology; 2004; 67(3-4):310-9. PubMed ID: 15557793
[TBL] [Abstract][Full Text] [Related]
23. IKBKE phosphorylation and inhibition of FOXO3a: a mechanism of IKBKE oncogenic function.
Guo JP; Tian W; Shu S; Xin Y; Shou C; Cheng JQ
PLoS One; 2013; 8(5):e63636. PubMed ID: 23691078
[TBL] [Abstract][Full Text] [Related]
24. Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-κB/IκBα pathway.
Ch'ng WC; Abd-Aziz N; Ong MH; Stanbridge EJ; Shafee N
Cell Oncol (Dordr); 2015 Aug; 38(4):279-88. PubMed ID: 25930675
[TBL] [Abstract][Full Text] [Related]
25. FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia.
Sakoe Y; Sakoe K; Kirito K; Ozawa K; Komatsu N
Blood; 2010 May; 115(18):3787-95. PubMed ID: 20215638
[TBL] [Abstract][Full Text] [Related]
26. The inhibition of activated hepatic stellate cells proliferation by arctigenin through G0/G1 phase cell cycle arrest: persistent p27(Kip1) induction by interfering with PI3K/Akt/FOXO3a signaling pathway.
Li A; Wang J; Wu M; Zhang X; Zhang H
Eur J Pharmacol; 2015 Jan; 747():71-87. PubMed ID: 25498792
[TBL] [Abstract][Full Text] [Related]
27. FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.
Marzi L; Combes E; Vié N; Ayrolles-Torro A; Tosi D; Desigaud D; Perez-Gracia E; Larbouret C; Montagut C; Iglesias M; Jarlier M; Denis V; Linares LK; Lam EW; Martineau P; Del Rio M; Gongora C
Br J Cancer; 2016 Nov; 115(10):1223-1233. PubMed ID: 27685445
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms regulating the nuclear translocation of p38 MAP kinase.
Gong X; Ming X; Deng P; Jiang Y
J Cell Biochem; 2010 Aug; 110(6):1420-9. PubMed ID: 20506250
[TBL] [Abstract][Full Text] [Related]
29. Histone H3 phosphorylation at serine 10 and serine 28 is mediated by p38 MAPK in rat hepatocytes exposed to ethanol and acetaldehyde.
Lee YJ; Shukla SD
Eur J Pharmacol; 2007 Nov; 573(1-3):29-38. PubMed ID: 17643407
[TBL] [Abstract][Full Text] [Related]
30. FOXO3a and Posttranslational Modifications Mediate Glucocorticoid Sensitivity in B-ALL.
Consolaro F; Ghaem-Maghami S; Bortolozzi R; Zona S; Khongkow M; Basso G; Viola G; Lam EW
Mol Cancer Res; 2015 Dec; 13(12):1578-90. PubMed ID: 26376801
[TBL] [Abstract][Full Text] [Related]
31. Streptococcus pneumoniae-induced p38 MAPK-dependent phosphorylation of RelA at the interleukin-8 promotor.
Schmeck B; Zahlten J; Moog K; van Laak V; Huber S; Hocke AC; Opitz B; Hoffmann E; Kracht M; Zerrahn J; Hammerschmidt S; Rosseau S; Suttorp N; Hippenstiel S
J Biol Chem; 2004 Dec; 279(51):53241-7. PubMed ID: 15485852
[TBL] [Abstract][Full Text] [Related]
32. Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK-3-MKK7-dependent mechanism.
Muniyappa H; Das KC
Cell Signal; 2008 Apr; 20(4):675-83. PubMed ID: 18222647
[TBL] [Abstract][Full Text] [Related]
33. The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression.
Hui RC; Gomes AR; Constantinidou D; Costa JR; Karadedou CT; Fernandez de Mattos S; Wymann MP; Brosens JJ; Schulze A; Lam EW
Mol Cell Biol; 2008 Oct; 28(19):5886-98. PubMed ID: 18644865
[TBL] [Abstract][Full Text] [Related]
34. Cocaine up-regulation of the norepinephrine transporter requires threonine 30 phosphorylation by p38 mitogen-activated protein kinase.
Mannangatti P; Arapulisamy O; Shippenberg TS; Ramamoorthy S; Jayanthi LD
J Biol Chem; 2011 Jun; 286(23):20239-50. PubMed ID: 21498515
[TBL] [Abstract][Full Text] [Related]
35. Involvement of the JNK/FOXO3a/Bim Pathway in Neuronal Apoptosis after Hypoxic-Ischemic Brain Damage in Neonatal Rats.
Li D; Li X; Wu J; Li J; Zhang L; Xiong T; Tang J; Qu Y; Mu D
PLoS One; 2015; 10(7):e0132998. PubMed ID: 26171786
[TBL] [Abstract][Full Text] [Related]
36. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization.
Gioeli D; Black BE; Gordon V; Spencer A; Kesler CT; Eblen ST; Paschal BM; Weber MJ
Mol Endocrinol; 2006 Mar; 20(3):503-15. PubMed ID: 16282370
[TBL] [Abstract][Full Text] [Related]
37. The role of Akt/FoxO3a in the protective effect of venlafaxine against corticosterone-induced cell death in PC12 cells.
Wang H; Zhou X; Huang J; Mu N; Guo Z; Wen Q; Wang R; Chen S; Feng ZP; Zheng W
Psychopharmacology (Berl); 2013 Jul; 228(1):129-41. PubMed ID: 23494228
[TBL] [Abstract][Full Text] [Related]
38. Nerve growth factor inhibits apoptosis in memory B lymphocytes via inactivation of p38 MAPK, prevention of Bcl-2 phosphorylation, and cytochrome c release.
Torcia M; De Chiara G; Nencioni L; Ammendola S; Labardi D; Lucibello M; Rosini P; Marlier LN; Bonini P; Dello Sbarba P; Palamara AT; Zambrano N; Russo T; Garaci E; Cozzolino F
J Biol Chem; 2001 Oct; 276(42):39027-36. PubMed ID: 11495898
[TBL] [Abstract][Full Text] [Related]
39. Roles of phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase in the regulation of protein kinase C-alpha activation in interferon-gamma-stimulated macrophages.
Hardy PO; Diallo TO; Matte C; Descoteaux A
Immunology; 2009 Sep; 128(1 Suppl):e652-60. PubMed ID: 19740326
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Sakai A; Ochi M
Cancer Chemother Pharmacol; 2008 Jun; 62(1):111-6. PubMed ID: 17874104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
